Coya Therapeutics Inc (COYA) Stock Price, Quote & News

Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 587 8170

Website: coyatherapeutics.com

Address:

5850 San Felipe St., Suite 500, Houston, United States

Jwa68 Oct. 3 at 7:34 PM

$COYA Sub $6 was such a gift in my mind. Added 30K shares just under it a month or so ago. Remains one of my top ideas.

0 · Reply

ap20 Oct. 3 at 7:31 PM

$COYA Anybody adding today?

1 · Reply

DB32022 Oct. 3 at 4:27 PM

$COYA https://meeting.neals.org/_files/ugd/bd7e5f_7a081efaa6d848c3afc765868c20fc17.pdf final presentation of conference

0 · Reply

Jwa68 Oct. 3 at 10:30 AM

$COYA

0 · Reply

Jwa68 Oct. 2 at 11:43 AM

$COYA Lucid note out $20 target. External Validation for Therapeutic Rationale Behind COYA 302

1 · Reply

Jwa68 Oct. 1 at 11:31 PM

$COYA Remains one of the most compelling value opportunities in the space in my opinion. High quality management, goals completely alligned with shareholders and a strong balance sheet. My target remains$18-$24 in an acquisition by Dr. Reddy’s. DYDD...

1 · Reply

RunnerSignals Sep. 30 at 8:54 PM

Hot Analyst Picks 🔥 $VKTX $COYA $AARD $PEPG $TNDM are making waves! big upside vibes on $VKTX but don’t sleep on $PEPG hot momentum https://stocksrunner.com/news/2025-09-30-top-analyst-picks-for-september-30

0 · Reply

irf944 Sep. 30 at 2:17 PM

$COYA BTIG Reiterates Buy on Coya Therapeutics, Maintains $15 Price Target. ChartMill assigns a Buy % Consensus number of 83% to COYA. The Buy consensus is the weighted average rating of the current analysts ratings. Analysts have set a mean price target forecast of 16.98. This target is 198.87% above the current price. COYA was analyzed by 13 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about COYA. COYA was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.

0 · Reply

Jwa68 Sep. 29 at 5:37 PM

$COYA Did anyone watch the Webinar with Dr. Berry? Such a top doctor believes in the science and approach. Stellar team COYA seems to have built to ensure success of this trial. Dr.Berry mentioned just one component of Coya-302 has shown benefit in ALS. So I would guess Coya-302 can only be better. This seems like a de-risked asset with good probability that the trial will be successful. Excellent asymmetric risk with an existing partnership with Dr. Reddy’s and a strong balance sheet.

2 · Reply

Robby83 Sep. 29 at 4:54 PM

$COYA nice candle on the daily divergence!

0 · Reply

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Sep 22, 2025, 8:00 AM EDT - 12 days ago

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Sep 16, 2025, 8:00 AM EDT - 18 days ago

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Sep 4, 2025, 8:00 AM EDT - 4 weeks ago

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

Sep 3, 2025, 11:50 AM EDT - 4 weeks ago

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Sep 3, 2025, 8:34 AM EDT - 4 weeks ago

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Aug 25, 2025, 8:00 AM EDT - 5 weeks ago

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Aug 12, 2025, 8:00 AM EDT - 7 weeks ago

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Jul 24, 2025, 8:15 AM EDT - 2 months ago

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Jul 22, 2025, 8:15 AM EDT - 2 months ago

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Jun 18, 2025, 8:15 AM EDT - 3 months ago

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Jun 2, 2025, 8:00 AM EDT - 4 months ago

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

May 16, 2025, 10:53 AM EDT - 5 months ago

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 13, 2025, 8:00 AM EDT - 5 months ago

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

May 8, 2025, 8:15 AM EDT - 5 months ago

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

May 8, 2025, 5:00 AM EDT - 5 months ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

REPL

Apr 25, 2025, 11:27 AM EDT - 5 months ago

Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release

Apr 24, 2025, 8:15 AM EDT - 5 months ago

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Apr 21, 2025, 9:51 AM EDT - 5 months ago

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Apr 1, 2025, 8:15 AM EDT - 6 months ago

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Mar 26, 2025, 8:15 AM EDT - 6 months ago

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Mar 18, 2025, 8:15 AM EDT - 7 months ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Feb 25, 2025, 8:15 AM EST - 7 months ago

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Feb 7, 2025, 5:17 PM EST - 8 months ago

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Feb 7, 2025, 1:53 PM EST - 8 months ago

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch

Feb 6, 2025, 1:30 PM EST - 8 months ago

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Feb 6, 2025, 8:00 AM EST - 8 months ago

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Feb 4, 2025, 8:15 AM EST - 8 months ago

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 21, 2025, 8:15 AM EST - 9 months ago

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Dec 18, 2024, 8:15 AM EST - 10 months ago

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Nov 25, 2024, 8:15 AM EST - 11 months ago

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Nov 19, 2024, 8:15 AM EST - 11 months ago

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Nov 6, 2024, 8:00 AM EST - 11 months ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Nov 1, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Oct 31, 2024, 10:31 AM EDT - 1 year ago

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

Oct 29, 2024, 2:36 PM EDT - 1 year ago

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Oct 29, 2024, 6:41 AM EDT - 1 year ago

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

Oct 23, 2024, 4:05 PM EDT - 1 year ago

Coya Therapeutics Announces Closing of $10.0 Million Private Placement

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Coya Therapeutics Announces $10.0 Million Private Placement

Oct 13, 2024, 4:17 AM EDT - 1 year ago

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Oct 8, 2024, 9:15 AM EDT - 1 year ago

Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100

Sep 24, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference

Sep 16, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson's Disease

Sep 3, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Present at Upcoming Healthcare Conferences

Aug 19, 2024, 9:00 AM EDT - 1 year ago

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results

Aug 2, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid

Jul 31, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Jwa68 Oct. 3 at 7:34 PM

$COYA Sub $6 was such a gift in my mind. Added 30K shares just under it a month or so ago. Remains one of my top ideas.

0 · Reply

ap20 Oct. 3 at 7:31 PM

$COYA Anybody adding today?

1 · Reply

DB32022 Oct. 3 at 4:27 PM

$COYA https://meeting.neals.org/_files/ugd/bd7e5f_7a081efaa6d848c3afc765868c20fc17.pdf final presentation of conference

0 · Reply

Jwa68 Oct. 3 at 10:30 AM

$COYA

0 · Reply

Jwa68 Oct. 2 at 11:43 AM

$COYA Lucid note out $20 target. External Validation for Therapeutic Rationale Behind COYA 302

1 · Reply

Jwa68 Oct. 1 at 11:31 PM

1 · Reply

RunnerSignals Sep. 30 at 8:54 PM

0 · Reply

irf944 Sep. 30 at 2:17 PM

0 · Reply

Jwa68 Sep. 29 at 5:37 PM

2 · Reply

Robby83 Sep. 29 at 4:54 PM

$COYA nice candle on the daily divergence!

0 · Reply

pankooo Sep. 29 at 4:50 PM

$COYA todays presentation?

0 · Reply

prismmarketview Sep. 29 at 2:28 PM

(NASDAQ: $COYA) Coya Therapeutics has completed enrollment in its proof-of-concept study of low-dose IL-2 + CTLA4-Ig in Frontotemporal Dementia. Topline results expected in Q4 2025. https://prismmarketview.com/coya-therapeutics-completes-enrollment-in-frontotemporal-dementia-study/

0 · Reply

irf944 Sep. 29 at 2:16 PM

$COYA COYA THERAPEUTICS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT OF AN INVESTIGATOR-INITIATED, OPEN-LABEL STUDY WITH LOW-DOSE IL-2 AND CTLA4-IG COMBINATION TREATMENT IN PATIENTS WITH MILD TO MODERATE FRONTOTEMPORAL DEMENTIA Following the positive interim results of 5 patients announced in April 2025, the study has enrolled an additional 4 patients for a total of 9 FTD patients. The trial is progressing according to the study protocol and no serious adverse events or discontinuations due to safety issues have been reported. Study completion is anticipated in Q4 2025 with topline to follow. Following database lock and analysis of the data, the Company plans to release the results of the study. No serioys adverse side effects or discontinuation due to safety issues have been reported. Results in Q4. Nice news.

0 · Reply

JarvisFlow Sep. 29 at 1:48 PM

D. Boral Capital has adjusted their stance on Coya Therapeutics ( $COYA ), setting the rating to Buy with a target price of 18.

0 · Reply

Jwa68 Sep. 29 at 1:07 PM

$COYA Continued execution by a world class team. Deep value...DYDD

0 · Reply

microcapspeculator Sep. 29 at 12:58 PM

$COYA This basically ties right in with ALS trial. I bet the two trials are identical. Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia Sep 29, 2025

0 · Reply

Jwa68 Sep. 26 at 12:18 PM

$COYA ALS community appears excited about the trial, as one would expect. https://alsnewstoday.com/news/large-new-trial-testing-ability-coya-302-slow-als-progression/

0 · Reply

irf944 Sep. 25 at 6:47 PM

$COYA We are sitting on 2 major support lines. The 1st line goes back to Auguts 2024. The 2nd line goes back to January 2025. Plenty of catalysts in the upcoming quarter to bring us back above $7 and beyond. Shouldn't take much with the low float.

0 · Reply

irf944 Sep. 25 at 6:18 PM

$COYA Added. Company continues to deliver good news. Disconnect right now between stock price and value of company.

1 · Reply

Robby83 Sep. 24 at 3:25 PM

$COYA nice dip this morning, filled a few of my orders. Hopefully it was the last hammer down on this bear trend.

0 · Reply

Jwa68 Sep. 24 at 3:05 PM

$COYA Really considering adding a little size here. Such deep value imo.

0 · Reply

zamped1 Sep. 23 at 8:53 PM

$COYA The price here is just silly...Candidly did not see this coming esoecially with the green light on phase 2b...Thought we would be $8 to $9 by now...Great risk/reward here imo.

1 · Reply

Market Cap	102.03M
Revenue (ttm)	3.55M
Net Income (ttm)	-14.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-419.15%
Debt to Equity Ratio	0.00

Volume	67,300
Avg Vol	78,564
Day's Range	N/A - N/A
Shares Out	16.73M
Stochastic %K	92%
Beta	0.19
Analysts	Strong Sell
Price Target	$16.20